Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor

Molecular Endocrinology

Volumn 23, Issue 9, 2009, Pages 1360-1370

  Pippal, Jyotsna B ^a   Yao, Yizhou ^a   Rogerson, Fraser M ^a,b   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; DNA; FLUDROCORTISONE; GLUTATHIONE TRANSFERASE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PROGESTERONE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DESOXYCORTICOSTERONE; GLUTATHIONE TRANSFERASE; HUMANS; HYDROCORTISONE; LIGANDS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, MINERALOCORTICOID; SWINE; TWO-HYBRID SYSTEM TECHNIQUES;

MAMMALIA;

EID: 69449087342     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0032     Document Type: Article

References (41)

1. Rogerson FM, Fuller PJ 2000 Mineralocorticoid action. Steroids 65:61-73
2. Farman N, Rafestin-Oblin ME 2001 Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 280:F181-F192
3. Cachofeiro V, Miana M, de Las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J, Lahera V 2008 Aldosterone and the vascular system. J Steroid Biochem Mol Biol 109:331-335
4. Struthers AD 2004 Aldosterone in heart failure: pathophysiology and treatment. Curr Heart Fail Rep 1:171-175
5. Fuller PJ, Young MJ 2005 Mechanisms of mineralocorticoid action. Hypertension 46:1227-1235
6. Joëls M, Karst H, DeRijk R, de Kloet ER 2008 The coming out of the brain mineralocorticoid receptor. Trends Neurosci 31:1-7
7. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E 2008 A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 29:133-154
8. Pitt B 2004 Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217:53-58 (Pubitemid 38596629)
9. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA 2006 International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58:782-797
10. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275 (Pubitemid 17095145)
11. Rogerson FM, Fuller PJ 2003 Interdomain interactions in the mineralocorticoid receptor. Mol Cell Endocrinol 200:45-55
12. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990 (Pubitemid 26001674)
13. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. J Biol Chem 274:37219-37225 (Pubitemid 30016799)
14. 2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
15. Estébanez-Perpiñá E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ, Guy RK 2005 The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 280:8060-8068 (Pubitemid 40349704)
16. Rupprecht R, Arriza JL, Spengler D, Reul JM, Evans RM, Holsboer F, Damm K 1993 Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol 7:597-603 (Pubitemid 23138168)
17. Sturm A, Bury N, Dengreville L, Fagart J, Flouriot G, Rafestin-Oblin ME, Prunet P 2005 11-Deoxycorticosterone is a potent agonist of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor. Endocrinology 146:47-55
18. Oelkers W 2004 Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 217:255-261 (Pubitemid 38596651)
19. Tirard M, Almeida OF, Hutzler P, Melchior F, Michaelidis TM 2007 Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor. Mol Cell Endocrinol 268:20-29 (Pubitemid 46428473)
20. Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ, and Lombès M 2005 The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Mol Endocrinol 19:1158-1169 (Pubitemid 40594116)
21. Pascual-Le Tallec L, Kirsh O, Lecomte MC, Viengchareun S, Zennaro MC, Dejean A, Lombès M 2003 Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 17:2529-2542 (Pubitemid 37542215)
22. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP 1999 Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 13:910-924
23. Métivier R, Stark A, Flouriot G, Hübner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F 2002 A dynamic structural model for estrogen receptor-α activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019-1032 (Pubitemid 35453823)
24. Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, Rafestin-OblinME2000 Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol Endocrinol 14:1210-1221
25. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Ló pez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A 2007 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 148:363-373 (Pubitemid 46021469)
26. McPhaul MJ, Marcelli M, Tilley WD, Griffin JE, Isidro-Gutierrez RF, Wilson JD 1991 Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. J Clin Invest 87:1413-1421
27. Zoppi S, Wilson CM, Harbison MD, Griffin JE, Wilson JD, McPhaul MJ, Marcelli M 1993 Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation. J Clin Invest 91:1105-1112 (Pubitemid 23095288)
28. 2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101
29. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, Estess J, Warden MP, Gomez-Sanchez MT, Gomez-Sanchez EP 2006 Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343-1348 (Pubitemid 43244368)
30. 2)-and carboxyl-terminal interaction. Mech Ageing Dev 125:683-695
31. Thompson J, Saatcioglu F, Jänne OA, Palvimo JJ 2001 Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol 15:923-935 (Pubitemid 32510639)
32. He B, Gampe Jr RT, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM 2004 Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16:425-438 (Pubitemid 39504796)
33. White PC, Mune T, Agarwal AK 1997 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156 (Pubitemid 27076458)
34. Odermatt A, Atanasov AG2009 Mineralocorticoid receptors: Emerging complexity and functional diversity. Steroids 74:163-171
35. Yokota K, Shibata H, Kurihara I, Kobayashi S, Suda N, Murai-Takeda A, Saito I, Kitagawa H, Kato S, Saruta T, Itoh H 2007 Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem 282:1998-2010 (Pubitemid 47076701)
36. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T, Kato S 2002 Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 22:3698-3706 (Pubitemid 34525213)
37. Liu W, Wang J, Yu G, Pearce D 1996 Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Mol Endocrinol 10:1399-1406 (Pubitemid 26423230)
38. Pascual-Le Tallec L, Lombès M 2005 The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19:2211-2221 (Pubitemid 41252817)
39. Fuse H, Kitagawa H, Kato S 2000 Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol Endocrinol 14:889-899 (Pubitemid 32260501)
40. Lavery DN, McEwan IJ 2005 Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J 391:449-464
41. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD 2004 Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13:1677-1692 (Pubitemid 39173438)